Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis

Kardigan (NASDAQ:KARD) extends Phase 2 trial of ataciguat, targeting 2027 results. Study finds 27% of mild to moderate patients are fast progressors, with higher risks of valve repair and hospitalization. Cardiac dysfunction prevalent in 80% of patients. Baseline data shows valve calcium as an independent risk marker. Ataciguat's potential effects on valve and heart muscle remain under investigation.

Kardigan completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat, involving 156 patients with aortic stenosis. Primary endpoint data is expected in late 2027. The company will assess disease progression at Week 24 and update Phase 3 plans in early 2027. According to a real-world analysis, cardiac damage markers correlate with worse outcomes.

Kardigan Inc. (NASDAQ:KARD) completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat, enrolling 156 participants. The protocol was amended to assess aortic valve calcium at Week 48. Baseline data showed varying levels of aortic valve calcium and related conditions. Topline data is expected in late 2027. The company also presented findings from a retrospective analysis of aortic stenosis progression.

Kardigan, Inc. (KARD) filed an SEC Form 8-K — Regulation FD Disclosure. PRESS RELEASE Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis Primary endpoint of aortic valve calcium in KATALYST-AV to be assessed at Week 48 alo

Kardigan, Inc. (KARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatm

AST SpaceMobile (ASTS) announced plans to build its own reusable rocket, Blacklift, for launching satellites starting in late 2028. Firefly Aerospace (FLY) will supply engines, valued at over $1.3B. ASTS shares rose 7.05%, while FLY surged 36.8%. The deal includes $800M upfront, including ASTS shares, and adds to ASTS's cash burn and dilution.